Other grades of this product :
| Gilenia Basic information |
| Product Name: | Gilenia | | Synonyms: | 2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol;Fingolimod(FTY720);Gilenia;Fingolimod;2-Amino-2-[2-(4-octylphenyl)ethyl]-1,3-propandiol;FingoliMod Base;fenogliMod;1,3-Propanediol,2-aMino-2-[2-(4-octylphenyl)ethyl]- | | CAS: | 162359-55-9 | | MF: | C19H33NO2 | | MW: | 307.47 | | EINECS: | 1308068-626-2 | | Product Categories: | pharmaceutical intermediate;API | | Mol File: | 162359-55-9.mol |
| Gilenia Chemical Properties |
| Melting point | 103-105° | | Boiling point | 479.5±45.0 °C(Predicted) | | density | 1.016 | | storage temp. | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C | | solubility | Chloroform (Very Slightly, Heated), DMSO (Slightly, Heated), Methanol (Slightly, | | pka | 12.20±0.20(Predicted) | | form | Solid | | color | Off-White |
| Gilenia Usage And Synthesis |
| Chemical Properties | white solid | | Uses | Prophylaxis of organ rejection
in patients receiving allogenic renal transplants (sphingosine-1-phosphate receptor). | | Uses | Fingolimod is a novel immune modulator that prolongs allograft transplant survival in numerous models by inhibiting lymphocyte emigration from lymphoid organs. | | Definition | ChEBI: An aminodiol that consists of propane-1,3-diol having amino and 2-(4-octylphenyl)ethyl substituents at the 2-position. It is a sphingosine 1-phosphate receptor modulator used for the treatment of relapsing-remitting multiple sclerosis. A prodrug, fingolimo
is phosphorylated by sphingosine kinase to active metabolite fingolimod-phosphate, a structural analogue of sphingosine 1-phosphate. | | Clinical Use | Sphingosine 1-phosphate receptor modulator:Treatment of highly active relapsing-remitting
multiple sclerosis | | Drug interactions | Potentially hazardous interactions with other drugs
Anti-arrhythmics: possible increased risk of
bradycardia with amiodarone, disopyramide and
dronedarone.
Antifungals: concentration increased by
ketoconazole.
Beta-blockers: possibly increased risk of bradycardia.
Calcium channel blockers: possible increased risk of
bradycardia with diltiazem and verapamil. | | Metabolism | Transformed by reversible stereoselective phosphorylation
to the pharmacologically active (S)-enantiomer of
fingolimod phosphate. It is eliminated by oxidative
biotransformation mainly via the cytochrome P450
4F2 isoenzyme and subsequent fatty acid-like
degradation to inactive metabolites, and by formation of
pharmacologically inactive non-polar ceramide analogues
of fingolimod. The main enzyme involved in the
metabolism of fingolimod is partially identified and may
be either CYP4F2 or CYP3A4.
81% excreted as inactive metabolites in the urine and
<2.5% in the faeces as metabolites and unchanged drug. |
| Gilenia Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye